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Abstract: Cassette dosing of compounds for preclinical drug plasma pharmacokinetic analysis 
has been shown to be a powerful strategy within the pharmaceutical industry for increasing 
throughput while decreasing the number of animals used. Presented here for the first time is data 
on the application of a cassette dosing strategy for label-free tissue distribution studies. The aim 
of the study was to image the spatial distribution of eight non-proprietary drugs (haloperidol, 
bufuralol, midazolam, clozapine, terfenadine, erlotinib, olanzapine and moxifloxacin) in multiple 
tissues after oral and intravenous cassette dosing (4 compounds per dose route). An array of mass 
spectrometry imaging technologies, including matrix-assisted laser desorption ionization mass 
spectrometry imaging (MALDI MSI), liquid extraction surface analysis (LESA-MS/MS) and 
desorption electrospray ionization (DESI-MS) was used. Tissue analysis following intravenous 
and oral administration of discretely and cassette-dosed compounds demonstrated similar relative 
abundances across a range of tissues indicating that a cassette dosing approach was applicable.  
MALDI MSI was unsuccessful in detecting all of the target compounds, therefore DESI-MSI, a 
complementary mass spectrometry imaging technique was used to detect additional target 
compounds. In addition, by adapting technology used for tissue profiling (LESA-MS/MS) low 
spatial resolution mass spectrometry imaging (~1mm) was possible for all targets across all 
tissues. This study exemplifies the power of multi-platform MSI analysis within a 
pharmaceutical R&D environment.  Furthermore, we have illustrated that the cassette dosing 
approach can be readily applied to provide combined, label free pharmacokinetic and drug 
distribution data at an early stage of the drug discovery/development process while minimising 
animal usage.  
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Introduction 
The development of mass spectrometric analytical technologies has enabled pharmaceutical 
research and development to employ an increasingly wide array of high-throughput screening 
modalities. Compound optimization with early, parallel elucidation of the physiochemical and 
pharmacokinetic properties enables a broader choice of compound leads from which candidate 
drugs can be selected and has also been shown to reduce compound attrition in development [1]. 
The simultaneous dosing of drugs during in vivo research is typically termed cassette dosing 
(though also referred to as N-in-one dosing). Cassette dosing was first employed by 
pharmaceutical companies towards the end of the 1990’s, when simultaneous measurements of 
five compounds were made during the development of potential therapeutics for the treatment of 
benign prostatic hyperplasia[2]. Cassette dosing and analysis has been shown to be applicable for 
both orally[3] and intravenously[4] administered drugs. Factors that need to be considered when 
devising a cassette dosing experiment include: mass spectrometry instrumentation and LC 
requirements (positive or negative mode ionization); if drugs or their metabolites are likely to 
have common structures or fragmentation patterns; if compounds require specific formulation 
(solubility at specific pH) and careful attention should be given to the dose levels selected. While 
such factors can be mitigated for by the selection of appropriate combinations of compounds to 
be analyzed, there remains a risk of drug-drug interactions during in vivo administration. This 
topic is extensively discussed in several reviews on cassette dosing[5-7]. Interactions mainly arise 
around competition at clearance pathways. Other reported interactions including heteroactivation 
of clearance pathways, which is the activation of a metabolic enzyme by a second drug acting 
through an allosteric mechanism (acting on a site other than the active site). There is also the 
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chance of pharmacological and toxicological effects on organ blood flows and clearances[7]. 
However, during early drug discovery, the advantage of parallel preliminary experiments means 
that the risk of erroneous results from drug-drug interactions is outweighed by the saving in 
reduced time and cost, as non-cassette experiments will always be performed on compounds that 
are to be progressed later in the discovery pipeline. 
 
Traditionally discovery phase pharmacokinetic analysis has been performed using sensitive triple 
quadrupole mass spectrometers, usually in combination with rapid chromatography systems and 
operated with automated or semi automated optimization software[8]. This generic approach 
enables rapid quantification of chemically diverse compounds from biofluids or tissue 
homogenates. Whilst these methods are ideally suited for deriving pharmacokinetic parameters 
from homogeneous biofluids, they are less suitable to analysis of heterogeneous tissue samples. 
Furthermore, any tissue information from homogenates can be misleading due to factors such as 
residual blood concentration or dilution. Compound biodistribution information is usually 
collected at a later stage in a compounds life-cycle using techniques like quantitative whole body 
auto-radiography (qWBA)[9]. Such analysis retains distribution information lost during 
homogenization but have major limitations such as the need for a radiolabelled compound, 
rendering the technique impractical for discovery use. Label based techniques are also limited in 
their inability to distinguish a parent compound from any metabolites that still contain the label, 
hence producing an ambiguous representation of a compounds distribution.  
 
Mass spectrometry imaging (MSI)[10, 11], regarded as collection of multiple mass spectra by 
rastering across a tissue section in two dimensions and mass spectrometry profiling (MSP) [12-15], 
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generally regarded as collection of mass spectra at discrete points on a tissue section, have 
recently emerged as technologies that have the capability to obtain label-free compound 
biodistribution, relative abundance and quantitation data by analyzing tissue sections directly.  
Such methods enable the simultaneous analysis of drugs, metabolites, endogenous small 
molecules, lipids and peptides directly from tissue sections. Several comprehensive reviews 
describe methodologies [16-18]  utilizing a range of sample ionization methods. Matrix assisted 
laser desorption ionization (MALDI) is arguably the most effective for pharmaceutical research 
and is most commonly employed for MSI. However, alternative ionization methods such as 
desorption electrospray ionization (DESI) are amenable for use in MSI[25]. Techniques like liquid 
extraction surface analysis (LESA) can be used to increase the sensitivity of tissue analysis when 
target compounds cannot be detected by other MSI ionization methods but their use to date has 
been restricted to low spatial tissue profiling at only a few sampling positions across a tissue 
section[13]. While the origins of LESA and DESI can both be traced back to electrospray 
ionization they exhibit different but complementary strengths and weaknesses. LESA can have 
high sensitivity when used in selected reaction monitoring mode on a triple quadrupole MS but 
lacks the high spatial resolution that DESI is capable of providing. DESI in contrast can supply 
structure rich MS images (figure 1- DESI endogenous masses, showing multiplex analysis within 
the cassette dosed sections) at high spatial resolution (~ 50 µm)[25], but has less apparent 
sensitivity due to the decrease in sampling area. 
The utility of MSI is determined by the ability to detect the target compound at the level present 
in the sample and is determined by a number of factors such as the ionization efficiency and 
localized suppression caused by salts and endogenous compounds within the tissues. There is 
also a risk that the mass of the target compound is masked in the mass spectrum by endogenous 
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compounds or MALDI matrix adduct signal. Therefore ‘upfront’ MSI ionization assessments are 
routinely performed to detect target compound in tissue samples before undertaking extensive 
studies. The risk of failing to detect a target in a sample can be further mitigated by using the 
orthogonal MSI techniques previously alluded to, such as LESA and DESI, which are becoming 
increasingly popular as imaging tools. These ionization techniques are essentially based on 
generic nano-electrospray ionization and can be used to cover a much wider chemical space than 
MALDI which is limited by MALDI matrix selection. These ambient ionization techniques are 
often combined with triple quadrupole, ion trap or time of flight mass spectrometers offering 
increased sensitivity at the cost of lower spatial resolution. 
 
In a pharmacokinetic study multiple biofluid samples can be taken at required time points post 
dose, however samples for MSI require the termination of the subject animal and the dissection 
and sectioning of a target organ. This means that a greater number of animals are required to 
generate corresponding time course MSI data. Effective cassette dosed MSI experiments would 
be advantageous with a reduction in both the analytical turnaround time but also the animal 
handling and husbandry costs. Any significant reduction in the number of animals is 
advantageous, above and beyond cost savings and analysis time, as it is in keeping with industry 
wide aims to reduce, reuse and refine experimental animal numbers, the so called ‘3-Rs’.  
 
The research presented here outlines a novel strategy of mass spectrometry tissue imaging and 
profiling in routine intravenous and orally cassette dosed pharmacokinetic studies. MSI analysis 
was not adversely affected by cassette dosing and the tissue distribution data corresponds with 
the plasma pharmacokinetic (PK) analysis and highlights the advantage of gaining important 
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pharmacokinetic and distribution data from the same animals at an early phase of drug discovery. 
Demonstrated for the first time is enhanced tissue profiling technology (LESA) for low spatial 
resolution imaging. Furthermore, such analysis is combined with near cellular resolution MSI 
(~20µm) and demonstrates that a suite of instrumentation enables detection of all target 
compounds and therefore a multi-platform MSI strategy is required for effective pharmaceutical 
R&D. 
 
Material and methods 
Materials and reagents. Analytical grade acetonitrile, methanol and formic acid were obtained 
from Fisher Scientific (Loughborough, Leicestershire, UK). 2-methylbutane was obtained from 
Sigma-Aldrich (Poole, Dorset, UK). Test compounds were obtained in house from AstraZeneca 
compound management group (Macclesfield, Cheshire, UK) with the exception of moxifloxacin 
which was purchased from Sigma-Aldrich (Poole, Dorset, UK). MALDI-MS grade α-cyano-4-
hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB) were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). 
 
Animals. Adult male Hans Wistar rats (approximate weight 260g) were obtained from Charles 
River Laboratories (Margate, Kent, UK) and were acclimatized on site for a minimum of 3 days 
prior to dosing. Compounds administered by oral gavage and intravenous bolus injection (via the 
tail vein) were formulated in 5% dimethylsulfoxide/95% (30% w/v Captisol in water). Control 
animals were dosed with vehicle via the same administration route in each arm of the study.  
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Dosing and scheduling. An initial pilot study using intravenous administration consisted of; 1 
animal dosed with vehicle, 1 animal dosed discretely with haloperidol (2 mg/kg) and 2 animals 
were cassette dosed (2 mg/kg/compound, haloperidol, bufuralol, midazolam and clozapine). All 
intravenously dosed animals were euthanized at 15 minutes post dose. 
A more extensive study using oral administration consisted of; 1 animal was dosed with vehicle, 
2 animals were dosed discretely with moxifloxacin (25 mg/kg), 2 animals were dosed discretely 
with olanzapine (10 mg/kg) and 3 animals were cassette dosed (Moxifloxacin, olanzapine, 
erlotinib and terfenadine at 25, 10, 10 and 25 mg/kg respectively). Blood samples were taken at 
0.5, 1, 2, 3, 4 and 5 hrs post dose via the tail vein (0.2 mL) and 6 hrs via cardiac puncture (0.5 
mL), the blood was spun at 4500g for 2 mins to yield plasma (approximately 0.1 mL) which was 
subsequently stored at -20°C prior to analysis. Animals were euthanized at either 2 or 6 hrs post 
dose. 
All tissue dissection was performed by trained AstraZeneca staff (project license 40/3484, 
procedure number 10). Tissues (brain, kidneys, lungs and liver) were snap-frozen in  
2-methylbutane on dry-ice, subsequent transfer of tissues was done on dry-ice and samples were 
stored at -80oC until tissue processing.  
 
Tissue processing. Tissue sections were cut at a thickness of 14 μm and thaw mounted onto 
indium tin oxide (ITO) coated MALDI target slides (Bruker Daltonics, Bremen, Germany) or 
standard glass microscope slides (VWR, Leicestershire, UK). Sections were taken at 
approximately equal depth from all organs to allow visualization of similar structures between 
samples. Organ tissue sections from cassette dosed, discrete dosed and vehicle control animals 
were mounted adjacent on the same slides to minimize variability caused through variations in 
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matrix application or when analyzing separate MALDI targets. Tissue sections were analyzed 
randomly and non-sequentially to limit the risk of any observed variation in relative abundance 
being as a result in loss of analyzer sensitivity during the course of the analysis. Mounted tissue 
sections, were stored at −80°C until required. 
 
MALDI matrix application. Thaw mounted tissue sections were dried in a stream of nitrogen 
when removed from -80oC storage. Optical images were taken using a standard flat bed scanner 
(Seiko Epson, Negano, Japan) prior to MALDI matrix application. Matrix coating was applied as 
previously described for the analysis of small molecules using a pneumatic TLC sprayer (Sigma 
Aldrich) [19]  . Either 15 mL of CHCA (10 mg/mL, 50/50 v/v acetonitrile/water, 0.1% TFA) or 
DHB (70 mg/mL, 50/50 v/v acetonitrile/water, 0.1% TFA) was applied. Following matrix 
application all subsequent transportation was performed with samples sealed in container to limit 
effects of light and humidity on sample and matrix. For high spatial resolution, tissue sections 
were transferred from -80°C to a desiccator and dried for about 30 min prior to matrix coating. 
An optical image of the slide was acquired using a flatbed scanner (Epson perfection V500). The 
tissue was coated with DHB at a lower concentration of 35 mg/ml (50/50 v/v methanol/water, 
0.2% TFA) to reflect the more direct application of matrix and to prevent system blockages when 
using the TM-Sprayer™ Tissue MALDI Sample Preparation System (HTX Technologies, LCC, 
Carrboro, NC, USA). A flow rate of 80 µL/min, nitrogen pressure 8 psi and a spray nozzle 
temperature of 95°C was used for 2 passes and 90°C for a subsequent 4 passes of the tissue. 
 
MALDI mass spectrometry imaging. MALDI-MSI was initially performed using a MALDI q-
TOF MS (MALDI SYNAPT G2 HDMS, Waters Corporation, U.K.). The region of interest 
10 
 
selected for imaging was defined using HDI Imaging software (version 1.2, Waters Corporation, 
U.K.), where the spatial resolution was also set (100 μm). Positive ion data was acquired with the 
mass spectrometer set to sensitivity mode over the range of m/z 100–1200 with 300 laser shots 
per raster position using a 1 kHz laser. Optimization of the mass spectrometer was achieved by 
tuning acquisition settings while collecting data from a manually deposited control spot of the 
target compounds (0.5 μL of drug standard solution at approximately 2µM manually spotted onto 
the ITO target with equal volume of matrix in solution. Raw data was converted to image files 
via processing through Mass Lynx (version 4.1, Waters Corporation, U.K.), then viewed in HDI 
Imaging software (version 1.2, Waters Corporation, UK). Data was normalized by total ion 
current and subsequent image analysis was performed. Mass filter windows were selected with a 
precision of ± 0.04 Da. 
 
High mass resolution data were acquired on a 12 T SolariX FT-ICR (Bruker Daltonics, Billerica, 
MA) running SolariX control v1.5.0 build 103. Ions were excited (frequency chirp 48-500 kHZ 
at 100 steps of 25 μs) for 0.8 s to yield broadband 2 Mword time-domain data. Each mass 
analysis was the sum of 400 random laser sample positions across tissue.  Fast Fourier 
transforms and subsequent analyses were performed using DataAnalysis v 4.1 build 362.7  and 
Fleximaging v4.0 build 32 (Bruker Daltonics, Billerica, MA).  
 
High spatial resolution MSI experiments were carried out in positive reflectron mode over a 
mass range of m/z 150 to 900 using the UltrafleXtreme MALDI-TOF/TOF MS (Bruker 
Daltonics) equipped with a 2 kHz, smartbeam-II™ Nd:YAG laser.  Data was collected at a 
spatial resolution of 15 µm, summing up 500 laser shots/raster position. FlexImaging 3.0 (Bruker 
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Daltonics) was used for data analysis, normalization and molecular image extraction typically 
using mass selection window of ± 0.05 Da. 
 
DESI mass spectrometry imaging.  DESI MSI analysis was performed using an Exactive mass 
spectrometer (Thermo Fisher Scientific Inc., Bremen, Germany) operated in positive ion mode. 
The mass spectrometer was equipped with a custom-built automated DESI ion source. The mass 
resolution used for all measurements was set to 100,000. Mass spectra were collected in the mass 
range of m/z = 150-1300. Methanol/water (95:5 v/v) was used as the electrospray solvent at a 
flow-rate of 2.5 µL/min. Nebulising nitrogen was used as gas at a pressure of 10 bars. The height 
distance between the DESI sprayer and the sample surface was set to 2 mm with the distance 
between the sprayer and the inlet capillary set to 14 mm. The distance between the sample 
surface and the inlet capillary of the mass spectrometer was < 1 mm. The angle between the 
sprayer tip and the sample surface was set at 80°. For line scan experiments, the parameters 
described above were used with a scan speed of 150 µm/s. Imaging experiments were conducted 
using 150 µm spatial resolution. Image analysis consisted of individual horizontal line scans 
combined into imzML format using the imzML converter V.1.1.4.5 (www.maldi-msi.org).  All 
images were created using 0.01 Da bin size and were normalised to the total ion count (TIC) to 
compensate for signal instabilities. 
 
LESA mass spectrometry imaging. LESA MSI was performed using LESA-MS/MS on a 
Triversa Nanomate chip based electrospray ionization system (Advion, Ithaca, NY, USA) 
coupled to a QTRAP 5500 (AB Sciex, Framingham, MA, USA) mass spectrometer was operated 
in positive ion MRM mode. The LESA sampling method consisted of aspiration of a 0.9 µL 
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volume of extraction solution (Acetonitrile/water/Formic Acid 60/40/0.1 v/v/v). 0.5 µL of the 
solution was then dispensed at a height of 0.4 mm above the tissue with a 1s post dispense delay 
time, a liquid micro junction between the pipette tip and the sample was maintained throughout 
the procedure. 1.1 µL of sample was re-aspirated into the pipette tip prior to infusion via the 
nanomate chip for MS/MS analysis. Relative abundance was determined between samples by 
comparison of MRM transition intensity at m/z 326>291.2, 262.2>188.1, 327.1>269.9 and 
376.1>165.1 for midazolam, bufuralol, clozapine and haloperidol (intravenously dosed cassette) 
respectively and 402.1>261.1, 313.1>256.1, 394.1>278.0 and 472.2>436.2 for moxifloxacin, 
olanzapine, erlotinib and terfenadine (orally dosed cassette) and. LESA-MS/MS data was 
processed using a purpose built software package capable of extracting relative abundance values 
from Analyst 6.1 (ABSciex, Framingham, MA, USA). 
LESA-MS/MS images were created using in-house developed software capable of colour 
grading ion intensities acquired from each individual LESA spot in a heat map configuration. 
 
PK bioanalysis. Details of the preparation of bioanalytical stock solutions and the bioanalytical 
method used can be found in the supporting information. 
 
Results and discussion 
Obtaining knowledge of the abundance and spatial distribution of compounds in target tissue can 
be extremely valuable in drug discovery or during a toxicological investigation. An 
understanding of the distribution profile of candidate drugs can be fed back into project 
design/make/test cycles, allowing researchers to refine the properties of chemical series early in 
the drug discovery process. In order to use such distribution information effectively the analysis 
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techniques need to be high throughput while not compromising data quality. This study explores 
cassette dosing as a viable method of increasing throughput and decreasing the numbers of 
animals used in distribution studies using mass spectrometry imaging. Data quality was validated 
by comparing compounds dosed using the cassette approach with compounds that are dosed 
orally and intravenously as discrete formulations. 
Technical replicates were not performed due to instrument time constraints, number of samples 
involved and the cost of LESA consumables (specifically nanoESI emitters). However, 
reproducibility of MSI strategies have previously been reported and therefore where not 
considered to be required for these experiments where relative abundances were measured. If 
absolute quantitation was performed we would recommend technical replicate analysis to be 
performed. 
 
Test substance selection. Four compounds were selected for a pilot intravenous cassette dosing 
experiment. Haloperidol, a dopamine D2 antagonist, bufuralol, a β-adrenoceptor antagonist and 
midazolam, a GABA antagonist, were chosen at random, no data about prior MSI analysis has 
been published to date. Clozapine, a serotonin antagonist that has been used in several in-house 
studies and is known to be detectable by MALDI-MSI was added to the intravenous cassette to 
mitigate the risk of failing to detect all compounds in the pilot study by our primary analytical 
technique. 
A further four compounds were selected for a more extensive oral cassette dosing experiment. 
Terfenadine, a H1 receptor antagonist, has been analyzed by MSI following a 50 mg/kg dose 
(single oral dose) using a hybrid quadrupole-time-of-flight (QqTOF, QStar Pulsar, Applied 
Biosystems)[20] and at the same dose by LESA profiling (QTRAP 5500, AB Sciex)[13]. Erlotinib, 
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a tyrosine kinase inhibitor, was detected using a hybrid quadrupole-time-of-flight (QqTOF, 
QStar XL, AB/MDS Sciex))[21] following 5 mg/kg oral dose. Olanzapine, a dopamine D2 
antagonist was orally dosed at 8 mg/kg and detected using a MALDI time-of-flight (Autoflex, 
Bruker)[22]. The final compound in the cassette was moxifloxacin, a DNA gyrase inhibitor, 
detected on a FlashQuant QTRAP (AB Sciex) following oral dose at 25 mg/kg[23].   
 
Intravenous (IV) dosing. An initial intravenously dosed pilot study consisting of cassette dosed, 
discrete dosed and vehicle dosed animals was performed in order to confirm the proof of 
principle that cassette dosing and discrete dosing show a similar relationship in terms of relative 
distribution across different tissues. Animals were euthanized at 15 minutes post dose, with 
brain, kidney, liver and lung samples dissected and snap frozen in 2-methylbutane post mortem.  
 
Distribution of IV dosed compounds by MALDI-MSI. Brain, kidney, liver and lung sections 
(14 µm) were thaw mounted onto ITO coated microscope slides. Sections were arranged, as 
stated in the experimental, to minimize intra-analysis variability caused by matrix applications 
and inter-analysis variability. Typically 3 brain sections representing cassette dosed, discrete 
dosed and control were mounted on the same slide. Positive ion MALDI-MSI (MALDI Synapt 
Q-TOF, Waters, Manchester, UK) was employed to analyse brain and liver sections. DHB and 
CHCA were used as standard MALDI matrices with limited success. Haloperidol, bufuralol and 
midazolam were not detected with either matrix from either tissue type even though initial 
ionization testing in the absence of tissue had been positive using both matrices (data not shown). 
This poor response could be due to various factors such as ionization suppression from 
endogenous components and salts in the tissue and could be rectified by using an alternative 
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MALDI matrix, solvent system or by carefully optimized on slide washing of the tissue prior to 
matrix application [24] and analysis. Clozapine was detected on both tissue types using CHCA as 
the MALDI matrix, the relative distribution of clozapine at 15 minutes post dose in a sagittal 
brain section can be seen in figure 1, normalized by total ion count, at a spatial resolution of 100 
µm. 
 
Additional MSI analysis by LESA-MS/MS and DESI-MS. The failure of MALDI-MSI to 
detect several of the intravenously dosed compounds presented an opportunity to highlight the 
value of orthogonal analysis by other techniques. Figure 1 shows images of intravenously dosed 
sagittal brain sections analysed by LESA-MS/MS (1 mm spatial resolution) and coronal brain 
sections analysed by DESI-MS (150 µm spatial resolution). LESA-MS/MS detected all of the 
compounds in the saggital brain sections. Relative distribution of the compounds was largely 
around the frontal cortex with little distribution into the rear left and right hemispheres of the 
cerebrum. Cassette dosed and discrete dosed comparisons of haloperidol in the brain sections by 
LESA-MS/MS (figure 1) highlighted some differences in distribution, this is due to the in-house 
imaging program applying a rainbow scale to a narrow drug intensity window across the two 
sections, the actual distribution was relatively homogeneous throughout the tissue. Coronal brain 
tissue sections (14µm) were thaw mounted onto standard glass slides for accurate mass DESI-
MS analysis. Due to the requirement to place DESI-MS samples onto non-conductive glass 
slides, additional tissue sections were cut by cryostat and thaw-mounted. It was necessary to use 
a brain from a different animal (dosed and sacrificed under same conditions) as the first brain 
fractured during the remounting process. While this prevents inter-sample consistency it does 
allow the coronal DESI analysis to show symmetry in detected analytes and endogenous 
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compounds. Detection of haloperidol, bufuralol and clozapine at (mass±ppm) 376.1468 ± 
1.6217, 262.1795 ± 2.4945 and 327.1366 ± 1.5254 Da respectively was achieved (figure 1). 
Midazolam could not be detected with sufficient mass accuracy (326.0850 Da) from the tissue 
sections using DESI-MS. 
 
Oral (PO) dosing. A larger, more comprehensive study was designed to compare cassette 
dosing to discrete dosing after oral administration. Plasma analysis by LC-MS/MS revealed that 
cassette and discrete dosed animals were exposed to the test substances in all instances. 
Comparative plasma concentrations post dose for moxifloxacin and olanzapine were equivalent 
in cassette dosed versus discrete dosed animals (Figure S-1, Supporting Information), indicating 
that plasma exposures were not adversely affected by drug-drug interactions. PK parameters for 
each compound are listed in Table S-1, Supporting Information. The parameters exhibit 
reproducibility between orally administered cassette and discrete dosed moxifloxacin and 
olanzapine and provide an initial indication that the cassette dosing approach is valid. 
 
Distribution of PO dosed compounds by MALDI-MSI. Brain, kidney, liver and lung tissue 
sections (14 µm) were thaw mounted onto ITO coated microscope slides and were arranged in a 
similar order as the orally dosed sections to maintain a consistent approach, where possible 5 
sections mounted per slide, representing cassette dose 2hrs and 6 hrs, discrete dose 2 hrs and 6 
hrs and control tissue. The mass spectrometer sources was rigorously cleaned after every two 
analytical runs to limit the risk of any observed variation in relative abundance being as a result 
in loss of analyzer sensitivity during the course of the analysis. Positive ion MALDI-MSI 
(MALDI Synapt Q-TOF, Waters, Manchester, UK) was employed to analyse the kidney sections 
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and produced high quality MS images (Figure 2), normalized by total ion count, at a spatial 
resolution of 100 µm and signal thresholding consistent across samples. The spatial distribution 
and relative abundance of the test substances at the 2 h time point was homogeneous throughout 
the kidney tissue. Moxifloxacin and olanzapine distribution was relatively consistent between 
cassette and discrete dosed animals, with some minor differences which could be attributed to 
pharmacokinetic inter-animal variability (supported by the differences in plasma PK levels, 
suplemetary information table S-1) or the depth at which the section was cut from the kidney 
sample. At the 6 h time point the relative abundance of the test substances in the cassette dosed 
kidneys was approximately 6-fold lower in abundance than the 2 h time point for moxifloxacin. 
A reduction was also detected for olanzapine (30-fold lower), erlotinib (8-fold reduced) and 
terfenadine (3-fold deminished). This drop in relative abundance reflects the decrease in 
concentrations observed in the plasma samples between the two time points but was not directly 
comparable in terms of the drop in response in tissue versus the drop in concentration in plasma. 
Erlotinib and terfenadine were distributed in both the cortex and medulla of the kidney, with 
greater intensity in the medullary region, whereas moxifloxacin and olanzapine were more 
localized in the medulla of the kidney. The consistent relative abundance between the images for 
moxifloxacin and olanzapine at each time point for cassette and discrete dosing provides further 
validation of the cassette dosing approach. Liver and brain sections were also analyzed by 
MALDI-MSI to confirm detection of the test substances in the various tissue types (data not 
shown). 
 
Analysis of orally dosed tissues by LESA-MS/MS. An advantage of tissue sectioning is that 
from each sample, multiple, near identical tissue sections can be taken, allowing analysis such as 
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LESA-MS/MS and DESI-MS to be performed in addition to MALDI-MSI. LESA-MS/MS is 
based upon nano-electrospray ionization, a proven, robust technique that is capable of ionizing a 
wide variety of different chemical species. The combination of the ionization technique with 
sensitive tandem mass spectrometry offers a complimentary method of analysis to MALDI-MSI. 
MALDI by contrast is a much more complex process, subject to subtle changes in ablation, 
ionization and sensitivity due to matrix choice, matrix crystal size, preparation conditions and 
endogenous interferences from material in the tissue such as salts. These limitations of the 
technique lead to a lower than ideal success rate when working in a high throughput 
environment. LESA-MS/MS and other direct ionization techniques such as DESI-MS provide a 
way of bridging that gap, enabling MSI scientists to pass on meaningful distribution data to 
project teams. Kidney sections were analysed by LESA-MS/MS (QTRAP 5500, ABSciex, 
Framingham, MA, USA) to generate low spatial resolution (1 mm) mass spectrometry images. 
Figure 3 displays the images from the LESA-MS/MS analysis of the orally cassette dosed and 
discrete dosed sections. The images are generated using in-house developed software that creates 
a heat map of the mean ion intensity data from each LESA extraction (~125 extractions per 
kidney section). The LESA imaging data correlate well with the observations of the MALDI-
MSI data, showing a clear difference in the relative abundance of the test substances at 2 and 6 
hrs post dose and good reproducibility in terms of spatial distribution between cassette and 
discrete dosed compounds. 
 
High Resolution MSI. Lung sections were analysed by high mass resolution MS (12 T SolariX 
FT-ICR, Bruker Daltonics, Billerica, MA, USA) for confirmation of the presence of the test 
substances. Sample spectra are shown in Figure S-2, Supporting Information, the presence of 
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moxifloxacin, olanzapine, erlotinib and terfenadine at m/z 402.1824, 313.1481, 394.1761 and 
472.3210 is confirmed by accurate mass and comparison of each compound with a vehicle dosed 
sample. 
 
High spatial resolution MSI is a powerful tool that allows near cellular resolution. The higher 
spatial resolution images can be used to identify regions of tissue structure within organ tissue 
sections. Figure 4 shows a high spatial resolution image (20 µm, UltrafleXtreme MALDI-
TOF/TOF MS, Bruker Daltonics) of dosed lung section. Olanzapine (m/z 313) represented in 
green, is distributed throughout the lung tissue, while a blood vessel can be clearly seen in the 
optical image and is reflected in the MSI image as an area of high heme abundance (m/z 616). 
High spatial resolution MSI can highlight distribution of test substances into localized areas of 
tissue to demonstrate drug presence at the site of action and could be expanded further to confirm 
target engagement via changes in endogenous disease markers. 
 
Conclusions 
Cassette dosing is a widely adopted practice within pharmaceutical discovery research for 
plasma PK analysis. Here we have demonstrated for the first time its utility in PK tissue 
distribution studies using mass spectrometry imaging techniques. Cassette dosing fundamentally 
increases throughput, in this case by four-fold, greatly reducing what has traditionally been an 
analytical bottleneck. The combination of cassette dosed PK and drug distribution studies have 
many advantages; ethically the technique reduces the number of animals used, typically by 
around 75%; the combination also leads to a wealth of pharmacokinetic and distribution data 
being available at a much earlier stage of drug discovery and can lead to a much greater 
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confidence that compounds are present at the pharmacological site of action. It is also possible to 
measure and monitor compound abundance target tissue in response to dose or time. 
 
Mass spectrometry imaging covers a variety of relatively new and exciting technologies that can 
be used to study the regional abundance of xenobiotics within tissues, while also simultaneously 
measuring endogenous molecules. A single technique is yet to emerge that can successfully 
analyse the full scope of chemistries encountered in drug discovery, at sufficient sensitivity and 
with high spatial resolution. MALDI-MSI was successfully used to analyse orally cassette dosed 
tissue sections at 100 µm and at higher spatial resolution (15 µm). LESA-MS/MS was validated 
against the MALDI-MSI data. The success of MALDI-MSI to analyse the compounds in the oral 
cassette dosed study was contrasted against an intravenously dosed cassette study in which the 
technique had less success. LESA-MS/MS and DESI-MS were used to profile the relative 
distribution of the intravenously dosed compounds, at lower spatial resolution, but with a higher 
success rate.  
 
The cassette dosing strategy has been shown to be a successful approach to obtain early, 
combined pharmacokinetic and distribution data. Mass spectrometric imaging techniques have 
an increasingly important role to play in pharmaceutical R&D, with techniques being developed 
to provide more quantitative data and the expansion of MALDI-MSI, in particular, into areas of 
targeted and untargeted metabolomics. 
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Supporting information available 
Additional information is available as noted in the text. This material is available free of charge 
via the Internet at http://pubs.acs.org. 
 
Figure legends 
 
Figure 1.  Images of intravenously dosed compounds detected using LESA-MS/MS, MALDI-
MS and DESI-MS after cassette dosing or discrete dosing (haloperidol), highlighting the value of 
using orthogonal analytical techniques to cover a wider chemical space than that covered by 
MALDI-MS alone. 
Figure 2. MSI abundance distributions of cassette and discrete dosed compounds in rat kidney 
sections (14 µm) at 2 and 6 hrs post dose. Moxifloxacin and olanzapine distribution is 
comparable at the two time points validating the cassette approach. 
Figure 3. LESA-MS/MS abundance distributions of cassette and discrete dosed compounds in 
rat kidney sections (14 µm) at 2 and 6 hrs post dose. This data mirrors the MALDI-MSI data 
showing comparable distribution of moxifloxacin and olanzapine dosed discretly and by the 
cassette approach. 
Figure 4. High spatial resolution MSI (15 µm) of orally cassette dosed lung tissue showing an 
optical image describing the region of interest and MSI images of olanzapine (green) and heme 
(red). A blood vessel can be clearly seen with the compound being homogenously distributed 
over the rest of the tissue, highlighting the power of high resolution MSI. 
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Figure 2 
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Figure 3 
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Figure 4 
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